Targeted Delivery of Arctigenin Using Sialic Acid Conjugate-Modified Liposomes for the Treatment of Breast Cancer
Molecules · 04.01.2024 · 29 (1) · 278
DOI: 10.3390/molecules29010278 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 04.01.2024. Verfasst von Shunfang Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Center for New Drug Research and Development, Guangdong Pharmaceutical Univers…. Hauptthemen laut MEDLINE: Lignans, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Scientific Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Arctigenin (ATG) is a broad-spectrum antitumor drug with an excellent inhibitory effect on malignant tumors such as breast cancer, glioblastoma, liver cancer, and colon cancer. However, the clinical application of ATG is limited by its poor water solubility and quick hydrolysis in the liver, intestine, and plasma, which might hinder its application. Sialic acid (SA) recognizes selectin receptors overexpressed on the surface of tumor-associated macrophages. In this study, SA was conjugated with octadecylamine (ODA) to prepare SA-ODA, which was employed to prepare SA functionalized nanoliposomes (SA-Lip) to achieve breast cancer targeting. The formulations were finely optimized using the Box–Behnken design to achieve higher ATG loading. The size, ζ potential, entrapment efficiency, drug loading, and release behavior of ATG@SA-Lip were fully investigated in comparison with conventional ATG@Lip. The ATG@SA-Lip displayed more potent cytotoxicity and higher cellular internalization compared to ATG@Sol and ATG@Lip in both MCF7 and 4T1 cells. Notably, ATG@SA-Lip showed the lowest impact on the immune system. Our study demonstrates that SA-Lip has strong potential as a delivery system for the targeted delivery of ATG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Advanced Drug Delivery Systems, Center for New Drug Research and Development, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Guangdong High Education Institutes Engineering Research Center of Modified-Released Pharmaceutical Products, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China.
- Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China.
ORCID-Profile: Shunfang Liu, Yaozhen He, Yongtong Huang, Wenhao Wu
Förderung
- Medical Scientific Research Foundation of Guangdong Province
Zitieren
APA
Liu, S., He, Y., Feng, M., Huang, Y., Wu, W., & Wang, J. (2024). Targeted Delivery of Arctigenin Using Sialic Acid Conjugate-Modified Liposomes for the Treatment of Breast Cancer. Molecules, 29(1), 278. https://doi.org/10.3390/molecules29010278
Vancouver
Liu S, He Y, Feng M, Huang Y, Wu W, Wang J. Targeted Delivery of Arctigenin Using Sialic Acid Conjugate-Modified Liposomes for the Treatment of Breast Cancer. Molecules. 2024;29(1):278. doi:10.3390/molecules29010278
BibTeX
@article{Liu2024,
author = {Liu, Shunfang and He, Yaozhen and Feng, Minding and Huang, Yongtong and Wu, Wenhao and Wang, Jiu},
title = {Targeted Delivery of Arctigenin Using Sialic Acid Conjugate-Modified Liposomes for the Treatment of Breast Cancer},
journal = {Molecules},
year = {2024},
volume = {29},
number = {1},
pages = {278},
doi = {10.3390/molecules29010278}
}
EUVIMED